Innoviva Inc
NASDAQ:INVA

  • LAST PRICE
    19.1500
  • TODAY'S CHANGE (%)
    0.0900 (0.4722%)
  • Bid / Lots
    18.9400/ 8
  • Ask / Lots
    19.1000/ 1
  • Open / Previous Close
    19.0900 / 19.0600
  • Day Range
    19.0000
    19.2950
  • 52 Week Range
    13.4600
    21.2800
  • Volume
    894,114

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • Nov 12, 2024

      Show headlines and story abstract

    • 4:05PM ET on Tuesday Nov 12, 2024 by Dow Jones
      Companies Mentioned: INVA

      Innoviva to Participate in the UBS Global Healthcare Conference
      BURLINGAME, Calif.--(BUSINESS WIRE)--November 12, 2024--
      Innoviva, Inc. (NASDAQ: INVA) ("Innoviva" or the "Company"), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics ("IST"), and a portfolio of strategic investments in healthcare assets, today announced that management will participate in a fireside chat at the UBS Global Healthcare Conference in Ranch Palos Verdes, CA on Wednesday, November 13, 2024 at 10:15 a.m. Pacific Time.

  • Nov 6, 2024

      Show headlines and story abstract

    • 4:10PM ET on Wednesday Nov 06, 2024 by MT Newswires
      Companies Mentioned: INVA
      04:10 PM EST, 11/06/2024 (MT Newswires) -- ...

    • 4:05PM ET on Wednesday Nov 06, 2024 by Dow Jones
      Companies Mentioned: INVA
      liabilities $ 30,357 $ 33,435 Accrued interest payable 833 3,422 Deferred revenue 717 1,277 Convertible senior notes, due 2025, net 191,843 191,295 Convertible senior notes, due 2028, net 255,972 254,939 Other long-term liabilities 71,449 71,870 Deferred tax liabilities, net - 563 Income tax payable, long-term 11,899 11,751 Innoviva stockholders' equity 668,542 674,955 -------------------------------- ------------------------------- Total liabilities and stockholders' equity $ 1,231,612 $ 1,243,507 === ================================ =============================== INNOVIVA, INC. Cash Flows Summary (in thousands) (unaudited) Nine Months Ended September 30, ----------------------------------------------------- 2024 2023 --- ----------------- --------------------- Net cash provided by operating activities $ 129,451 $ 107,808 Net cash used in investing activities (48,308) (61,610) Net cash used in financing activities (14,026) (157,250) ----------------- --------------------- Net change 67,117 (111,052) Cash and cash equivalents at beginning of period 193,513 291,049 ----------------- --------------------- Cash and cash equivalents at end of period $ 260,630 $ 179,997 === ================= =====================

    • 4:05PM ET on Wednesday Nov 06, 2024 by Dow Jones
      Companies Mentioned: INVA
      liabilities $ 30,357 $ 33,435 Accrued interest payable 833 3,422 Deferred revenue 717 1,277 Convertible senior notes, due 2025, net 191,843 191,295 Convertible senior notes, due 2028, net 255,972 254,939 Other long-term liabilities 71,449 71,870 Deferred tax liabilities, net - 563 Income tax payable, long-term 11,899 11,751 Innoviva stockholders' equity 668,542 674,955 -------------------------------- ------------------------------- Total liabilities and stockholders' equity $ 1,231,612 $ 1,243,507 === ================================ =============================== INNOVIVA, INC. Cash Flows Summary (in thousands) (unaudited) Nine Months Ended September 30, ----------------------------------------------------- 2024 2023 --- ----------------- --------------------- Net cash provided by operating activities $ 129,451 $ 107,808 Net cash used in investing activities (48,308) (61,610) Net cash used in financing activities (14,026) (157,250) ----------------- --------------------- Net change 67,117 (111,052) Cash and cash equivalents at beginning of period 193,513 291,049 ----------------- --------------------- Cash and cash equivalents at end of period $ 260,630 $ 179,997 === ================= =====================

Peers Headlines